Smart Phone ACT Treatment for Adults With Longstanding Pain - a Pilot Study (ACTsmart)

January 20, 2020 updated by: Rikard Wicksell

ACTsmart - Feasibility of Smart Phone Delivered ACT Treatment for Adults With Longstanding Pain

The aims are to test feasibility and preliminary effects of a smart phone delivered ACT treatment for adults with longstanding pain.

The hypotheses are that

  1. ACTsmart will be a feasible and accessable treatment delivery form
  2. ACTsmart will improve function and quality of life

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Chronic pain affects 12-30% of the population and often results in depression, disability, and reduced daily function and quality of life. Medical strategies are often ineffective or insufficient to alleviate symptoms and increase functioning. Instead, the empirical support for cognitive behavior therapy (CBT) is today well established, and such interventions are commonly seen as critically important for patients with chronic pain. However, modest effects sizes calls for further improvements. Recent developments within CBT, particularly Acceptance and Commitment Therapy (ACT), have suggested the utility of acceptance and mindfulness strategies to manage pain and distress. The body of evidence for ACT has grown rapidly during the past decade, and ACT is today listed by the American Psychological Association as a treatment for chronic pain, with strong empirical support.

Internet-delivered ACT Despite the increased empirical support for ACT the availability is still very limited, and a large number of patients do not receive this treatment. In other domains, the accessibility of empirically supported treatments has increased during the past decade due to the development of methods to deliver the treatment via internet. For example, a large number of studies illustrate the utility of internet-delivered CBT for anxiety, insomnia and depression, with treatment effects similar to those obtained in studies with face-to-face treatment. Few studies have yet evaluated internet-delivered ACT (iACT) for chronic pain, but a recent pilot study from our group with participants suffering from fibromyalgia (n=41) illustrated very promising results that warrant further studies to evaluate the effects of this treatment.

To make treatment more accessible and present in patients' daily life we will use a smart phone application to deliver treatment.

Recruitment Patients will be recruited through self referral. Information regarding the study will be provided through newspapers and social media, as well as in direct communication with pain clinics and primary care units, including instructions regarding e.g. eligibility and how to sign up. Once patients have been found eligible and expressed interest in study participation they will be assessed by a psychologist, and when needed by a pain physician, via semi-structured interviews to confirm eligibility and to ensure that the patient meet the study criteria. Informed consent is obtained from all participants prior to the assessment.

Statistical methods Evaluations of treatment effects are primarily based on intent-to-treat analyses. The statistical approach will primarily be based on linear multilevel modeling (LMM), which takes into account dependencies between repeated measures and differences between patients in pre-treatment status and treatment response (i.e. random effects modeling) and also provide means of handling missing data. More traditional methods, such as ANOVA and hierarchical regression, may also be utilized when appropriate.

Interviews Evaluations of feasibility and as a base for further development of the smart phone application will be done via semi structured interviews during and after treatment period.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Stockholms Län
      • Stockholm, Stockholms Län, Sweden, 171 77
        • Karolinska Institutet

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • a pain duration of ≥ 6 months;
  • able to read and write in Swedish
  • have access to a smart phone with internet access
  • no planned changes in medication use, or any other changes in interventions for their pain planned

Exclusion Criteria:

  • injury or illness that require immediate assessment or different treatment, or that is expected to progress significantly during the next 6 months
  • unstable medication (planned changes in medication during next 4 months)
  • ACT or CBT treatment during the past 3 months
  • severe psychiatric co-morbidity (e.g. high risk of suicide) as assessed by the psychologist in a semi-structured interview

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: ACTsmart
ACT treatment via a smart phone application

Participant receive ACT treatment via a smart phone application, including psychologist support via a message function within the application.

Treatment content is divided into four modules:

  1. education about pain behaviors, exposure and acceptance and commitment therapy
  2. education about pain physiology
  3. exercises on changing behaviors, acceptance, mindfulness, defusion and exposure
  4. value based exposure in the participant's daily life

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain Interference Index (changes between assessments)
Time Frame: Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated measure of daily functioning related to pain
Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Psychological Inflexibility in Pain Scale (changes)
Time Frame: Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated psychological inflexibility related to pain. Total score min 12, max 84, lower values are interpreted as higher psychological flexibility, higher values interpreted as lower psychological flexibility. Two subscales; fusion (4-28) and avoidance (8-56) are summed to compute a total score.
Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment
Valuing Questionnaire (changes)
Time Frame: Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated progress and obstacles in valued actions. The Valuing Questionnaire consists of two subscales: progress (0-30) och obstacles (0-30). No total score is computed. On the obstacle subscale higher scores are worse, and on the progress subscale higher scores are better.
Baseline, 8 weekly ratings, post (8 weeks), follow ups three, six and twelve months post treatment
Patient Health Questionnaire 9 (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated depressive symptoms. Score is summed to a possible range of 0 to 27. Higher scores are interpreted as worse.
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
European Quality of Life Five Dimensions Questionnaire (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated quality of life. Scores are calculated to a number between 0 and 1, where 0 in theory is equal to death, and 1 is considered equal to perfect quality of life.
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Insomnia Severity Index (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated degree of insomnia
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Pain intensity (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated degree of pain during last week on a scale from 0-10
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Occupational status (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self reported occupational status indicated on a pre specified list, including sick leave and/or sick retirement
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Generalized Anxiety Disorder - 7 (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self rated symptoms of anxiety
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Medication use (changes)
Time Frame: Baseline, post (8 weeks), follow ups three, six and twelve months post treatment
Self reported medicine use
Baseline, post (8 weeks), follow ups three, six and twelve months post treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Collaborators

Investigators

  • Principal Investigator: Rikard Wicksell, Karolinska Institutet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 23, 2017

Primary Completion (Actual)

December 23, 2019

Study Completion (Actual)

December 23, 2019

Study Registration Dates

First Submitted

November 14, 2017

First Submitted That Met QC Criteria

November 14, 2017

First Posted (Actual)

November 17, 2017

Study Record Updates

Last Update Posted (Actual)

January 22, 2020

Last Update Submitted That Met QC Criteria

January 20, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2015/1638-31/2:2

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Chronic Pain

3
Subscribe